Cancer's genetic heterogeneity presents a significant hurdle in developing truly personalized medicine. While advancements in next-generation sequencing (NGS) have enabled comprehensive genomic profiling of tumors, translating this data into effective therapies faces substantial experimental challenges.  Identifying driver mutations amidst numerous passenger mutations remains complex, requiring sophisticated bioinformatic analyses and validation through functional assays.  Furthermore, the dynamic nature of cancer genomes, including intratumoral heterogeneity and the emergence of resistance mutations, necessitates longitudinal monitoring and the development of adaptive treatment strategies.  Preclinical models, while crucial, often inadequately mimic the complexity of human cancers, leading to discrepancies between in vitro and in vivo responses to targeted therapies.  The scarcity of patient-derived xenografts (PDXs) that accurately reflect the genetic landscape and microenvironment of individual tumors further limits the predictive power of preclinical studies.  Finally, the ethical considerations surrounding genomic data privacy and the cost-effectiveness of comprehensive genomic profiling pose significant barriers to widespread implementation of personalized cancer medicine, demanding further research and robust regulatory frameworks.